• E-mailAurora.Martinez@uib.no
  • Phone+47 55 58 64 27
  • Visitor Address
    Jonas Lies vei 91
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Aurora Martinez is the leader of the research group Biorecognition that studies the relation between biomolecular structure and function to understand and develop new therapeutic options for genetic diseases, notably neurometabolic disorders such as phenylketonuria (PKU) and defects in dopamine synthesis.

Aurora is also a partner in the KG Jebsen Centre for neuropsychiatric disorders. In addition, she is also a partner in the project 'Molecular control of Arc protein: Decoding a master regulator of synaptic plasticity and cognition', coordinated by Clive Bramham, which received support from the Toppforsk Program (NFR).

  • Show author(s) (2023). Impact of small molecule-mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism. Cancer Communications. 508-512.
  • Show author(s) (2022). Structural mechanism for tyrosine hydroxylase inhibition by dopamine and reactivation by Ser40 phosphorylation. Nature Communications.
  • Show author(s) (2022). Screening for modulators of vesicular monoamine transporter 2 activity in transfected Hek293 cells using a fluorescent substrate.
  • Show author(s) (2022). Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone. Communications Biology. 1-14.
  • Show author(s) (2022). High-throughput screening for VMAT2 activity modulators.
  • Show author(s) (2022). High-affinity anti-Arc nanobodies provide tools for structural and functional studies. PLOS ONE. 33 pages.
  • Show author(s) (2022). Does alpha-Synuclein modulate Tyrosine Hydoxylase activity?
  • Show author(s) (2022). Biochemical and biophysical characterisation of HMBS variants associated with acute intermittent porphyria.
  • Show author(s) (2021). The Pah-R261Q mouse reveals oxidative stress associated with amyloid-like hepatic aggregation of mutant phenylalanine hydroxylase. Nature Communications. 15 pages.
  • Show author(s) (2021). Personalized medicine to improve treatment of dopa-responsive dystonia—a focus on tyrosine hydroxylase deficiency. Journal of Personalized Medicine. 28 pages.

More information in national current research information system (CRIStin)

Research groups